Genta Ishikawa, MD, MPH

Built on a strong foundation of academic training as a pulmonologist in Japan and the United States, Dr. Ishikawa has an enduring passion for pioneering innovative treatments for pulmonary fibrosis. After completing his clinical training in Japan, Dr. Ishikawa sought to broaden his medical expertise in the United States. He honed his research skills and expanded his knowledge base by earning a Master of Public Health (MPH) degree from Emory University.

Driven by his relentless pursuit of excellence, Dr. Ishikawa further bolstered his credentials by undertaking an Internal Medicine Residency and a Fellowship in Pulmonary Critical Care and Sleep Medicine at Mount Sinai, New York. During this comprehensive clinical training, he faced the harsh realities of pulmonary fibrosis — a relentless, fatal form of progressive interstitial lung disease (ILD). This impactful experience galvanized Dr. Ishikawa to dedicate his career to devising innovative treatments for this severe condition.

Committed to advancing his mission, Dr. Ishikawa embarked on a postdoctoral fellowship at Yale University under the expert guidance of the esteemed Dr. Erica L. Herzog. As part of his role, he also has the privilege of caring for ILD patients at the Yale Center for Interstitial Lung Diseases, an experience that lends practical insights to his research work.

Currently, within the intellectually stimulating environment of Dr. Herzog's laboratory, Dr. Ishikawa is investigating a recently discovered neuro-innate fibrotic mechanism. This intriguing mechanism entails complex interactions between nerve-derived noradrenaline and lung macrophages that express alpha-1 adrenoreceptors.

Guided by a vision to transform the treatment landscape for pulmonary fibrosis, Dr. Ishikawa's ultimate goal is to translate these intricate scientific findings into potent, effective therapies. He remains staunchly dedicated to this pursuit, propelled by the hope that his research will contribute significantly to advancing patient care.